Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ofirmev® Clear all
Recruiting Phase 2 Interventional

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT06043323
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Not listed Not applicable Interventional

KITAMS: Kinesio Tape and Physical Function in Persons With Multiples Sclerosis

NCT03804047
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
kinesio tape
Other
Lead sponsor
Northern Illinois University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Not applicable Interventional

Predicting Analgesic Response to Acupuncture: A Practical Approach

NCT02890810
View directory record Official record
Conditions
Chronic Low Back Pain, Back Pain
Interventions
Real Acupuncture with Electrical Stimulation, Simulated Acupuncture with Electrical Stimulation
Other
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 16, 2026, 2:18 AM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
Device · Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional

A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy

NCT00402792
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

NCT00404391
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Owing Mills, Maryland • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2011 · Synced Sep 16, 2026, 2:18 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain

NCT07225634
View directory record Official record
Conditions
Acute Pain
Interventions
Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 16, 2026, 2:18 AM EDT
Terminated Phase 2 Interventional Results available

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

NCT01745913
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, Rabbit ATG, Double Umbilical Cord Blood Transplantation, Haplo-Identical Cord Transplantation
Device · Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 16, 2026, 2:18 AM EDT
Not listed Phase 4 Interventional

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

NCT05863221
View directory record Official record
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gingival Augmentation Around Implants During Maintenance

NCT02904551
View directory record Official record
Conditions
Failure of Dental Implant Due to Lack of Attached Gingiva
Interventions
Free gingival graft, Oral prophylaxis
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 16, 2026, 2:18 AM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Maxigesic® IV Phase 3 Exposure Study

NCT04005755
View directory record Official record
Conditions
Postoperative Pain
Interventions
Maxigesic® IV
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Pasadena, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

NCT00818493
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride), Percocet (oxycodone and acetaminophen)
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 16, 2026, 2:18 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02508935
View directory record Official record
Conditions
Acute Pain
Interventions
XARTEMIS XR
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

NCT01382940
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Early Phase 1 Interventional

Systemic Normothermia in Intracerebral Hemorrhage (ICH)

NCT02078037
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Arctic Sun cooling device, Standard of Care
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Not applicable Interventional

Characterizing the Effects of Platelet-Rich Fibrin (PRF) as a Palatal Wound Dressing on Quality of Life and Sleep Following Mucogingival Surgery. Study Was Conducted at the Air Force Post Graduate Dental School. All HIPPA Consents and Research Informed Consents Are Located at JBSA-Lackland.

NCT07637838
View directory record Official record
Conditions
Palatal Donor Site Wound Healing, Platelet Rich Fibrin, Sleep Quality, Pain, Analgesic Consumption
Interventions
Platelet rich fibrin, Control Group: collagen matrices or oxidized cellulose membrane
Procedure · Other
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco

NCT01456520
View directory record Official record
Conditions
Healthy
Interventions
Vycavert, Norco
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 16, 2026, 2:18 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912
View directory record Official record
Conditions
Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 16, 2026, 2:18 AM EDT